Adherence to postoperative thromboprophylactic medication among gynecologic oncology patients: A subanalysis.

[1]  J. Sheeder,et al.  Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm , 2020, JAMA network open.

[2]  D. Duverger,et al.  Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. , 2020, New England Journal of Medicine.

[3]  J. Sheeder,et al.  African American women with advanced-stage ovarian cancer have worse outcomes regardless of treatment type , 2020, International Journal of Gynecological Cancer.

[4]  F. Andreis,et al.  Longitudinal study of the relationship between patients’ medication adherence and quality of life outcomes and illness perceptions and beliefs about cardiac rehabilitation , 2020, BMC Cardiovascular Disorders.

[5]  C. Flowers,et al.  Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  V. García-Cárdenas,et al.  Temporal effectiveness of interventions to improve medication adherence: A network meta-analysis , 2019, PloS one.

[7]  P. Wells,et al.  Apixaban to Prevent Venous Thromboembolism in Patients with Cancer , 2019, The New England journal of medicine.

[8]  Dana P Goldman,et al.  Racial and ethnic disparities in medication adherence among privately insured patients in the United States , 2019, PloS one.

[9]  G. Lyman,et al.  Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. , 2019, Thrombosis research.

[10]  M. Abdul Hadi,et al.  Association between medication adherence and quality of life of patients with diabetes and hypertension attending primary care clinics: a cross-sectional survey , 2018, Quality of Life Research.

[11]  J. Chabot,et al.  Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer , 2018, Journal of Gastrointestinal Surgery.

[12]  J. Williamson,et al.  Patient-Reported Outcome Measures (PROM) as A Preoperative Assessment Tool , 2017, Journal of anesthesia and perioperative medicine.

[13]  D. Wheeler,et al.  Estimating an area-level socioeconomic status index and its association with colonoscopy screening adherence , 2017, PloS one.

[14]  K. Blumenschein,et al.  Quality of Life and Medication Adherence of Independently Living Older Adults Enrolled in a Pharmacist-Based Medication Management Program , 2017, Pharmacy.

[15]  A. Khorana,et al.  Cancer and Venous Thromboembolic Disease: A Review. , 2017, The oncologist.

[16]  Yuan Gao,et al.  The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery , 2016, SpringerPlus.

[17]  A. Lamblin,et al.  Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. , 2016, Thrombosis research.

[18]  E. Upchurch,et al.  Post-operative use of Low Molecular Weight Heparin: Are patients doing their bit? , 2016 .

[19]  Mohamed M. Ghoneim,et al.  Depression and postoperative complications: an overview , 2016, BMC Surgery.

[20]  A. Maraveyas,et al.  Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology , 2015, Haematologica.

[21]  F. Germini,et al.  Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. , 2015, Chest.

[22]  M. Stenman,et al.  Relation of major depression to survival after coronary artery bypass grafting. , 2014, The American journal of cardiology.

[23]  C. Spies,et al.  Preoperative depression and hospital length of stay in surgical patients. , 2014, Minerva anestesiologica.

[24]  D. Pieper,et al.  Adherence influencing factors in patients taking oral anticancer agents: a systematic review. , 2014, Cancer epidemiology.

[25]  V. Bae-Jump,et al.  Preoperative quality of life and surgical outcomes in gynecologic oncology patients: a new predictor of operative risk? , 2014, Gynecologic oncology.

[26]  M. Menon,et al.  Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. , 2014, JAMA surgery.

[27]  L. Sharp,et al.  Traveling Towards Disease: Transportation Barriers to Health Care Access , 2013, Journal of Community Health.

[28]  P. Amstislavski,et al.  Medication deserts: survey of neighborhood disparities in availability of prescription medications , 2012, International Journal of Health Geographics.

[29]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. , 2010, The New England journal of medicine.

[30]  T. Wakefield,et al.  Venous Thromboembolism in Cancer Patients Undergoing Major Surgery , 2008, Annals of Surgical Oncology.

[31]  Roger. T. Anderson,et al.  Race and medication adherence in Medicaid enrollees with type-2 diabetes. , 2006, Journal of the National Medical Association.

[32]  L. Sands,et al.  Are preoperative depressive symptoms associated with postoperative delirium in geriatric surgical patients? , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[33]  C. Colwell,et al.  Patient compliance with outpatient prophylaxis: an observational study. , 2005, Orthopedics.

[34]  N. Chaudri.  Adherence to Long-term Therapies Evidence for Action , 2004, Annals of Saudi Medicine.

[35]  A. Cohen,et al.  Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. , 2002, The New England journal of medicine.